Soraya Bekkali, M.D.Chief Executive Officer at Gyroscope Therapeutics
Soraya is a board-certified MD graduated from Paris University specialized in Clinical Pharmacology and Biostatistics with 20 years of experience in Drug Development. She started her career in the academia before joining the industry with Orphan Europe, a European based company dedicated to the development and commercialisation of orphan drugs.
She then joined Sanofi for 10 years where she held increasing leadership positions within R&D, leading global drug development programs in cardiovascular and Ophthalmology. In 2012, she took over the leadership of the Ophthalmology Division created following the acquisition by Sanofi of a biotech, Fovea Pharmaceuticals, and in this capacity, drove Sanofi strategy towards ocular gene therapy efforts while setting up a multidisciplinary R&D and business organization.
Soraya transitioned from Big Pharma to Biotech in 2016, by first serving as SVP CMO at Lysogene, a Boston-Paris biotech developing gene therapy treatment for rare CNS disorders. As a member of the executive team, she contributed to the successful listing of the company on the European Stock Exchange Euronext. Mid 2017, she was appointed CEO and director of the board of Gyroscope therapeutics, a UK based company developing genetically defined therapies for ocular diseases such as age related macular degeneration. Over the last 2 years, she has set up and led the organisation towards clinical stage with the first patient treated as of last January. An account of the ground-breaking treatment was the subject of a recent BBC News broadcast: https://www.bbc.co.uk/news/health-47226987.